Home › Compare › CPIHF vs ABBV
CPIHF yields 12500.00% · ABBV yields 3.06%● Live data
📍 CPIHF pulled ahead of the other in Year 1
Combined, CPIHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CPIHF + ABBV for your $10,000?
Champion Technology Holdings Limited, an investment holding company, primarily engages in the trading of gasoil and cultural products, sales of renewable energy systems and related engineering work, software development, and licensing and customization of system products in the People's Republic of China, the United Kingdom, and Germany. The company operates through five segments: Sales of Cultural Products, Sales of Surveillance Equipment, Renewable Energy, Trading for Gasoil and Related Business, and Strategic Investments. It is involved in the sales of cultural products, gasoil, and surveillance equipment; design and sale of renewable energy products and solutions; charters vessels; general system products; and provision of systems and related software licensing services, as well as installation and maintenance services; and payment gateways and Internet of Things services. The company also offers e-shopping, Internet-based, e-commerce, and m-commerce services; invests in and leases properties; advertising and recruitment agency services; and trades in pagers and provides messaging services, as well as telecommunication system and products. In addition, it provides management, documentation, and arrangement and business consultant services; messaging services; and consulting, research and development, and telecommunication services. Further, the company engages in the money lending activities; and investing in listed securities. Champion Technology Holdings Limited is based in Shek Tong Tsui, Hong Kong.
Full CPIHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.